Home › Chronic Myelomonocytic Leukemia › Washington › Seattle

Pag-aaral pangklinika para sa Chronic Myelomonocytic Leukemia sa Seattle, WA

Isang pag-aaral para sa Chronic Myelomonocytic Leukemia ang naghahanap ng mga kalahok sa isang site sa loob o malapit sa Seattle. Buksan ito upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.

Opisyal na teksto ng pag-aaral (English)

Nagha-hire para sa pag-aaral dito? I-highlight ito sa tuktok ng pahinang ito — $99 sa loob ng 30 araw →

CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia

Nagre-recruitPhase 1

Fred Hutch/University of Washington Cancer Consortium, Seattle

Edad 18 pataas · Lahat ng kasarian · Na-update Set 17, 2026 · NCT04375631

Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer

Nagre-recruitPhase 2

Fred Hutch/University of Washington Cancer Consortium, Seattle

Edad 18 pataas · Lahat ng kasarian · Na-update Hul 20, 2026 · NCT07046078

211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome

Nagre-recruitPhase 1/2

Fred Hutch/University of Washington Cancer Consortium, Seattle

Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Hun 22, 2026 · NCT03670966

211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia

Nagre-recruitPhase 1/2

Fred Hutch/University of Washington Cancer Consortium, Seattle

Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Hun 22, 2026 · NCT03128034

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

Nagre-recruitPhase 2Malugod na tinatanggap ang malusog na boluntaryo

Fred Hutch/University of Washington Cancer Consortium, Seattle

6 Months · Lahat ng kasarian · Na-update May 29, 2026 · NCT04195633

HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

Nagre-recruitPhase 1

Fred Hutch/University of Washington Cancer Consortium, Seattle

Hanggang edad 80 · Lahat ng kasarian · Na-update May 18, 2026 · NCT03326921

Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse

Nagre-recruitPhase 1/2Malugod na tinatanggap ang malusog na boluntaryo

Fred Hutch/University of Washington Cancer Consortium, Seattle

Edad 18 pataas · Lahat ng kasarian · Na-update May 15, 2026 · NCT06928662

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

Nagre-recruitPhase 2/3

Seattle Cancer Care Alliance, Seattle

Edad 18 pataas · Lahat ng kasarian · Na-update Abr 30, 2026 · NCT04256317

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

Nagre-recruitPhase 2

Fred Hutchinson Cancer Center, Seattle

Edad 18 hanggang 66 · Lahat ng kasarian · Na-update Mar 17, 2026 · NCT06859424

Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)

Nagre-recruitPhase 1

Fred Hutchinson Cancer Center, Seattle

Edad 18 pataas · Lahat ng kasarian · Na-update Abr 15, 2025 · NCT06462365

Pag-aaral para sa Chronic Myelomonocytic Leukemia sa ibang lungsod

Iba pang pag-aaral sa Seattle

Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.